Gut health biotech Microba seeks $20m to fund UK acquisition

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 57 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 26%
  • Publisher: 90%

日本 ニュース ニュース

日本 最新ニュース,日本 見出し

The company its brokers Bell Potter and Morgans rounding up offers at 23¢ a piece.

ASX-listed biotech Microba Life Sciences pressed play on a $20 million equity raise on Thursday morning to fund the acquisition of a UK microbiome company.

Microba Life Sciences chairman Ian Frazer, CEO Luke Reid and co-founder Gene Tyson at the listing ceremony in April 2022. Microba had its brokers Bell Potter and Morgans rounding up offers at 23¢ a piece, a 28 per cent discount to the last close. Proceeds will be used to acquire Invivo Clinical for $21.1 million, a Gloucestershire-based that develops microbiome tests and supplements.

Microba’s major shareholder, ASX-listed Sonic Healthcare will participate in the raise. The pathology business owns around 20 per cent of the company and is taking up the offer pro rata. Other major shareholders include Perennial Value Management and the Thorney Investment Group. Microba, which counts renowned immunologist and inventor of the technology behind the HPV cervical cancer Gardasil vaccine, Professor Ian Frazer, as deputy chairman, hashas co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.is a co-editor of the Street Talk column.

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 2. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し